didn't quite follow this stock, just came across this:
ICPT
Intercept's OCA drug linked with worsened cholesterol levels
Patients who received Intercept Pharmaceuticals' (ICPT) beticholic acid (OCA
) for the treatment of NASH in a trial for the chronic liver disease
experienced increased bad cholesterol and lower good cholesterol, the NIH
said after the close on Friday in a statement to the WSJ.The NIH said it was
releasing the information to give "broader context" to its earlier findings
that O... 阅读全帖
